Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY COMPARING EFFICACY AND SAFETY OF FREXALIMAB (SAR441344) TO PLACEBO IN ADULT PARTICIPANTS WITH NONRELAPSING SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS

Intervention/treatment:
FREXALIMAB (SAR441344)
Medical condition:
MULTIPLE SCLEROSIS
Protocol code:
EFC17504
Control number:
282862
Status:
Active, not recruiting
Approved:
February 13, 2024
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT06141486
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 60 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Trial Transparency email recommended (Toll free number for US & Canada)
Role
CONTACT
Phone:
800-633-1610
Extension option 6
Sponsor
SANOFI-AVENTIS CANADA INC

Locations

Alberta

Investigational Site Number : 1240011
Calgary, Alberta, T2N 2T9
RECRUITING

British Columbia

Investigational Site Number : 1240005
Burnaby, British Columbia, V5G 2X6
RECRUITING
Investigational Site Number : 1240010
Vancouver, British Columbia, V6T 2B5
RECRUITING

New Brunswick

Investigational Site Number : 1240018
Moncton, New Brunswick, E1C 2Z3
RECRUITING

Ontario

Investigational Site Number : 1240002
Ottawa, Ontario, K1H 8L6
RECRUITING
Investigational Site Number : 1240012
Toronto, Ontario, M5B 1W8
RECRUITING
Investigational Site Number : 1240014
London, Ontario, N6A 5A5
RECRUITING
Investigational Site Number : 1240015
Toronto, Ontario, M4N 3M5
RECRUITING

Quebec

Investigational Site Number : 1240001
Gatineau, Quebec, J8Y 1W2
RECRUITING
Investigational Site Number : 1240003
Québec, Quebec, G1J 1Z4
RECRUITING
Investigational Site Number : 1240006
Sherbrooke, Quebec, J1H 5N4
RECRUITING
Investigational Site Number : 1240008
Lévis, Quebec, G6W 0M5
RECRUITING
Investigational Site Number : 1240009
Montreal, Quebec, H2X 3E4
RECRUITING
Did you find what you were looking for?